Multifocal motor neuropathy (MMN) is now a well-defined purely motor multineuropathy characterized by the presence of multifocal partial motor conduction blocks (CB), frequent association with anti-GM1 IgM antibodies, and usually a good response to high-dose intravenous immunoglobulin (IVIg) therapy. However, several issues remain to be clarified in the diagnosis, pathogenesis, and therapy of this condition including its nosological position and its relation to other chronic dysimmune neuropathies; the degree of CB necessary for the diagnosis of MMN; the existence of an axonal form of MMN; the pathophysiological basis of CB; the pathogenetic role of antiganglioside antibodies; the mechanism of action of IVIg treatments in MMN and the most effective regimen; and the treatment to be used in unresponsive patients. These issues are addressed in this review of the main clinical, electrophysiological, immunological, and therapeutic features of this neuropathy. (copyright) 2005 Wiley Periodicals, Inc.

Multifocal motor neuropathy : Current concepts and controversies / E. Nobile-Orazio, A. Cappellari, A. Priori. - In: MUSCLE & NERVE. - ISSN 0148-639X. - 31:6(2005), pp. 663-680.

Multifocal motor neuropathy : Current concepts and controversies

E. Nobile-Orazio
Primo
;
A. Priori
Ultimo
2005

Abstract

Multifocal motor neuropathy (MMN) is now a well-defined purely motor multineuropathy characterized by the presence of multifocal partial motor conduction blocks (CB), frequent association with anti-GM1 IgM antibodies, and usually a good response to high-dose intravenous immunoglobulin (IVIg) therapy. However, several issues remain to be clarified in the diagnosis, pathogenesis, and therapy of this condition including its nosological position and its relation to other chronic dysimmune neuropathies; the degree of CB necessary for the diagnosis of MMN; the existence of an axonal form of MMN; the pathophysiological basis of CB; the pathogenetic role of antiganglioside antibodies; the mechanism of action of IVIg treatments in MMN and the most effective regimen; and the treatment to be used in unresponsive patients. These issues are addressed in this review of the main clinical, electrophysiological, immunological, and therapeutic features of this neuropathy. (copyright) 2005 Wiley Periodicals, Inc.
drug mechanism; drug megadose; drug response; electrophysiology; human; immunopathogenesis; immunotherapy; motor nerve conduction; motor neuropathy; nerve block; neuropathology; plasmapheresis; priority journal; review; azathioprine; beta1a interferon; cyclophosphamide; cyclosporin; ganglioside GM1; ganglioside antibody; immunoglobulin M; immunoglobulin; monoclonal antibody; mycophenolic acid 2 morpholinoethyl ester; rituximab; steroid
Settore MED/26 - Neurologia
2005
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/15105
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 178
  • ???jsp.display-item.citation.isi??? 136
social impact